Dr. Blagosklonny discusses the drawbacks of osimertinib in lung cancer treatment and proposes preemptive combinations to increase PFS without harm. The podcast delves into the effectiveness of different combinations for EGFR mutant lung cancer and MET-driven lung cancer.

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center #published a new brief #report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.” “In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.” DOI - https://doi.org/10.18632/oncoscience.593 Corresponding author - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com Sign up for free Altmetric alerts about this article - https://oncoscience.altmetric.com/details/email_updates?id=10.18632%2Foncoscience.593 Subscribe for free publication alerts from Oncoscience - https://www.oncoscience.us/subscribe/ Keywords - cancer, lung cancer, brain metastases, capmatinib, resistance, MET About Oncoscience Oncoscience is a traditional, peer-reviewed, bio-medical oncology research journal with FREE publication for authors and open-access for readers. To learn more about Oncoscience, please visit https://www.oncoscience.us/ and connect with us: Facebook - https://www.facebook.com/Oncoscience X - https://twitter.com/OncoscienceJrnl Instagram - https://www.instagram.com/oncosciencejrnl/ YouTube - https://www.youtube.com/@OncoscienceJournal LinkedIn - https://www.linkedin.com/company/oncoscience/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researcher Mikhail V. Blagosklonny discusses how rapamycin and other rapalogs can delay cancer by targeting pre-cancerous cells and slowing organismal aging. Clinical trials in high-risk populations are warranted to explore their cancer-preventive effects.

Oncologist and researcher Mikhail V. Blagosklonny discusses using antagonistic drug combinations to protect normal cells while targeting drug-resistant cancer cells for improved treatment outcomes and reduced side effects.

Dr. Mikhail V. Blagosklonny discusses using clinically approved drugs to extend lifespan by inhibiting signaling pathways, emphasizing the importance of combination therapy for optimal results in geroscience.